Principal Financial Group Inc. Buys 5,480 Shares of TransMedics Group, Inc. (NASDAQ:TMDX)

Principal Financial Group Inc. raised its holdings in shares of TransMedics Group, Inc. (NASDAQ:TMDX) by 2.8% in the first quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 198,427 shares of the company’s stock after purchasing an additional 5,480 shares during the period. Principal Financial Group Inc. owned 0.59% of TransMedics Group worth $13,350,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also made changes to their positions in the business. Teacher Retirement System of Texas bought a new position in shares of TransMedics Group during the first quarter valued at approximately $330,000. Clear Creek Financial Management LLC increased its position in shares of TransMedics Group by 5.8% during the first quarter. Clear Creek Financial Management LLC now owns 5,963 shares of the company’s stock valued at $401,000 after acquiring an additional 325 shares in the last quarter. Vontobel Holding Ltd. bought a new stake in shares of TransMedics Group during the first quarter valued at approximately $291,000. Peregrine Capital Management LLC increased its position in shares of TransMedics Group by 3.4% during the first quarter. Peregrine Capital Management LLC now owns 68,390 shares of the company’s stock valued at $4,601,000 after acquiring an additional 2,250 shares in the last quarter. Finally, Taylor Frigon Capital Management LLC increased its position in shares of TransMedics Group by 28.1% during the first quarter. Taylor Frigon Capital Management LLC now owns 31,540 shares of the company’s stock valued at $2,122,000 after acquiring an additional 6,922 shares in the last quarter. Institutional investors own 99.67% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts recently weighed in on TMDX shares. Needham & Company LLC reissued a “hold” rating on shares of TransMedics Group in a research report on Tuesday, June 17th. Oppenheimer lifted their target price on shares of TransMedics Group from $130.00 to $150.00 and gave the stock an “outperform” rating in a research report on Tuesday, June 17th. Finally, Piper Sandler reaffirmed an “overweight” rating and issued a $145.00 target price (up previously from $125.00) on shares of TransMedics Group in a research report on Wednesday, June 4th. Three equities research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, TransMedics Group currently has an average rating of “Moderate Buy” and a consensus target price of $127.33.

Insider Activity at TransMedics Group

In other TransMedics Group news, Director David Weill sold 732 shares of the business’s stock in a transaction on Friday, May 23rd. The shares were sold at an average price of $123.88, for a total value of $90,680.16. Following the sale, the director owned 12,134 shares in the company, valued at $1,503,159.92. The trade was a 5.69% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Edward M. Basile sold 6,000 shares of the business’s stock in a transaction on Friday, May 9th. The stock was sold at an average price of $115.63, for a total transaction of $693,780.00. Following the completion of the sale, the director owned 732 shares in the company, valued at approximately $84,641.16. The trade was a 89.13% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 12,418 shares of company stock worth $1,512,613. 7.00% of the stock is owned by corporate insiders.

TransMedics Group Trading Down 9.9%

Shares of TMDX stock opened at $112.46 on Friday. TransMedics Group, Inc. has a 1 year low of $55.00 and a 1 year high of $177.37. The firm has a fifty day moving average price of $125.49 and a 200-day moving average price of $90.65. The company has a debt-to-equity ratio of 1.92, a current ratio of 9.10 and a quick ratio of 8.32. The company has a market cap of $3.80 billion, a price-to-earnings ratio of 82.69 and a beta of 2.06.

TransMedics Group (NASDAQ:TMDX) last released its earnings results on Thursday, May 8th. The company reported $0.70 earnings per share for the quarter, beating analysts’ consensus estimates of $0.29 by $0.41. TransMedics Group had a net margin of 10.03% and a return on equity of 21.88%. The company had revenue of $143.54 million for the quarter, compared to analysts’ expectations of $123.39 million. During the same quarter in the previous year, the company earned $0.35 EPS. TransMedics Group’s revenue for the quarter was up 48.2% on a year-over-year basis. As a group, equities analysts predict that TransMedics Group, Inc. will post 1 earnings per share for the current year.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.